Word: colonics
(lookup in dictionary)
(lookup stats)
Dates: during 2000-2009
Sort By: most recent first
(reverse)
DIED. GISELE MACKENZIE, 76, Canadian-born singer and 1950s TV star; of colon cancer; in Burbank, Calif. The daughter of a Winnipeg doctor, she was a regular on Your Hit Parade, where she and such co-stars as Snooky Lanson and Dorothy Collins would perform the top seven songs of each week. She was later a regular on The Sid Caesar Show and starred in her own short-lived variety series...
ERBITUX Martha Stewart may have still more reason to regret selling her ImClone stock. In June, ImClone reported that its drug Erbitux, in combination with chemotherapy, reduced tumor growth in the colon up to 55%, putting the controversial drug on track for FDA consideration. Erbitux targets cancer cells by blocking their ability to absorb growth factors they need to develop. Trials for treating other tumors, including those in the lung, head and neck, are under...
When NBC television personality Katie Couric underwent a colonoscopy live on national TV in March 2000, she did more than show the world the insides of her bowels. Couric, whose husband died from colon cancer at age 42, also significantly raised the rate at which Americans signed up for a colon-cancer screening. In a study that appears in the current issue of the Archives of Internal Medicine, a team of researchers from Michigan and Iowa reports that colonoscopy rates across the U.S. jumped more than 20% following Couric's examination...
...that may translate into saved lives. More than 130,000 Americans this year will be found to have colon cancer, and more than 56,000 will die from the disease, making it the second leading cause of cancer deaths, according to the National Cancer Institute. Many of these deaths could have been avoided if people were not so squeamish about undergoing colonoscopy, which is what makes the "Katie Couric effect," as researchers have dubbed it, so important. --By David Bjerklie
...Since the stock market started to find its footing last July, U.S. biotech shares have risen 57%. Another bubble? Not necessarily. Many of the companies have marched steadily closer to bringing products to market. MedImmune's inhalable flu preventive FluMist was approved in mid-June. In May, Genentech's colon-cancer drug Avastin stunned scientists with its effectiveness in trials and is widely expected to be approved soon. Dozens of other products are in the works. "We're starting to see the fruits of biotech research," says Kenneth Carter, ceo of Avalon Pharmaceuticals, which is working on three cancer drugs...